Following the realization that cerebral tissue may survive for hours after an ischaemic insult, several agents with neuroprotective properties in small-animal models of cerebral ischaemia have been tested in patients with acute ischaemic stroke (AIS). Initial attempts at translating the positive effects of these agents from animal models to patients were unsuccessful, possibly as a result of poorly planned experiments in models of ischaemia, and/or clinical trials of AIS that were not optimized to show a positive effect. Newer neuroprotective agents that are believed to act later in the ischaemic cascade may offer a greater chance of success. However, before these agents can be introduced into clinical practice they must undergo assessment in rodent and large-animal models of AIS and, in particular, the dose-response relationship and the treatment time window should be defined. This should be followed by evaluation in carefully designed clinical trials of adequate power, involving subjects receiving an appropriate dose within an optimum time window following the onset of symptoms. There is hope that such careful strategies may guide continued progress in neuroprotective drug development.

Keywords:
Neuroprotection, Stroke, Ischaemia
1.
World Health Organization: Statistical Information System. World Health Organization, 2004.
2.
American Heart Association: Heart Disease and Stroke Statistics – 2005 Update. Dallas, American Heart Association, 2005.
3.
Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999;22:391–397.
4.
Biller J, Love BB: Nihilism and stroke therapy. Stroke 1991;22:1105–1107.
5.
Fisher M: Recommendations for advancing development of acute stroke therapies: stroke therapy academic industry roundtable 3. Stroke 2003;34:1539–1546.
6.
Klijn CJ, Hankey GJ: Management of acute ischaemic stroke: new guidelines from the American Stroke Association and European Stroke Initiative. Lancet Neurol 2003;2:698–701.
7.
Furlan AJ, Katzan IL, Caplan LR: Thrombolytic therapy in acute ischemic stroke. Curr Treat Options Cardiovasc Med 2003;5:171–180.
8.
Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768–774.
9.
Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM: Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001;56:1015–1020.
10.
Cocho D, Belvis R, Marti-Fabregas J, Molina-Porcel L, Diaz-Manera J, Aleu A, Pagonabarraga J, Garcia-Bargo D, Mauri A, Marti-Vilalta JL: Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology 2005;64:719–720.
11.
Alexandrov AV, Hall CE, Labiche LA, Wojner AW, Grotta JC: Ischemic stunning of the brain: early recanalization without immediate clinical improvement in acute ischemic stroke. Stroke 2004;35:449–452.
12.
Graham GD: Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 2003;34:2847–2850.
13.
Heller RF, Dobson AJ: Disease impact number and population impact number: population perspectives to measures of risk and benefit. BMJ 2000;321:950–953.
14.
Ovbiagele B, Kidwell CS, Starkman S, Saver JL: Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke. Curr Treat Options Cardiovasc Med 2003;5:441–449.
15.
Gladstone DJ, Black SE, Hakim AM: Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002;33:2123–2136.
16.
Wahlgren NG, Ahmed N: Neuroprotection in cerebral ischaemia: facts and fancies – the need for new approaches. Cerebrovasc Dis 2004;17(suppl 1):153–166.
17.
Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW: NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:588–600.
18.
Shuaib A LK, Grotta J, Lyden P, Davalos A, Davis SM, Diener HC, Wasiewski W, Wilmington DE, Ashwood T, Hardemark HG, Emeribe U; for the SAINT investigators: SAINT ll: results of the second randomized, multicenter, placebo-controlled, double-blind study of NXY-09 treatment in patients with acute ischemic stroke. Int Stroke Conf, 2007.
19.
Fisher M: The ischemic penumbra: identification, evolution and treatment concepts. Cerebrovasc Dis 2004;17(suppl 1):1–6.
20.
Richard Green A, Odergren T, Ashwood T: Animal models of stroke: do they have value for discovering neuroprotective agents? Trends Pharmacol Sci 2003;24:402–408.
21.
Hossman K: Thresholds of ischemic injury; in Ginsberg MD, Bogousslavsky J (ed): Cerebrovasular Disease: Pathophysiology, Diagnosis and Management. Malden, Blackwell Science, 1988, pp 193–204.
22.
Beresford IJ, Parsons AA, Hunter AJ: Treatments for stroke. Expert Opin Emerg Drugs 2003;8:103–122.
23.
Zornow MH, Prough DS: Neuroprotective properties of calcium-channel blockers. New Horiz 1996;4:107–114.
24.
Yeung PK: Dp-b99 (d-pharm). Curr Opin Investig Drugs 2004;5:90–94.
25.
Jackson DM, Sammut IA: Oxygen free radical traps for the treatment of ischemia-associated organ injury. Curr Opin Investig Drugs 2004;5:50–54.
26.
Lodder J, Luijckx G, van Raak L, Kessels F: Diazepam treatment to increase the cerebral GABAergic activity in acute stroke: a feasibility study in 104 patients. Cerebrovasc Dis 2000;10:437–440.
27.
Lutsep HL: Repinotan Bayer. Curr Opin Investig Drugs 2002;3:924–927.
28.
Takahashi M, Kohara A, Shishikura J, Kawasaki-Yatsugi S, Ni JW, Yatsugi S, Sakamoto S, Okada M, Shimizu-Sasamata M, Yamaguchi T: Ym872: a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist. CNS Drug Rev 2002;8:337–352.
29.
Muir KW: Magnesium in stroke treatment. Postgrad Med J 2002;78:641–645.
30.
Blondeau N, Heurteaux C: Cerebral tolerance: a promising choice towards new treatments for neurologic diseases (in French). Méd Sci (Paris) 2004;20:1109–1114.
31.
Curry SH: Why have so many drugs with stellar results in laboratory stroke models failed in clinical trials? A theory based on allometric relationships. Ann NY Acad Sci 2003;993:69–74; discussion 79–81.
32.
Ovbiagele B, Kidwell CS, Starkman S, Saver JL: Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke. Curr Treat Options Neurol 2003;5:367–375.
33.
Hoyte L, Kaur J, Buchan AM: Lost in translation: taking neuroprotection from animal models to clinical trials. Exp Neurol 2004;188:200–204.
34.
Cheng YD, Al-Khoury L, Zivin JA: Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004;1:36–45.
35.
Muir KW, Lees KR: Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995;26:503–513.
36.
Sydserff SG, Borelli AR, Green AR, Cross AJ: Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat: studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 2002;135:103–112.
37.
Grotta J: Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke 2002;33:306–307.
38.
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581–1587.
39.
Lees KR: Neuroprotection is unlikely to be effective in humans using current trial designs: an opposing view. Stroke 2002;33:308–309.
40.
de Haan R, Limburg M, Bossuyt P, van der Meulen J, Aaronson N: The clinical meaning of rankin ‘handicap’ grades after stroke. Stroke 1995;26:2027–2030.
41.
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604–607.
42.
Duncan PW, Jorgensen HS, Wade DT: Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. Stroke 2000;31:1429–1438.
43.
Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752–2758.
44.
Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001;32:1598–1606.
45.
Warach S: Use of diffusion and perfusion magnetic resonance imaging as a tool in acute stroke clinical trials. Curr Control Trials Cardiovasc Med 2001;2:38–44.
46.
Green AR, Ashwood T, Odergren T, Jackson DM: Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059. Pharmacol Ther 2003;100:195–214.
47.
Wang CX, Shuaib A: NXY-059: a neuroprotective agent in acute stroke. Int J Clin Pract 2004;58:964–969.
48.
Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjo BK: Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1999;19:778–787.
49.
Zhao Z, Cheng M, Maples KR, Ma JY, Buchan AM: NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Res 2001;909:46–50.
50.
Marshall JW, Duffin KJ, Green AR, Ridley RM: NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 2001;32:190–198.
51.
Lees KR, Barer D, Ford GA, Hacke W, Kostulas V, Sharma AK, Odergren T: Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke 2003;34:482–487.
52.
Marshall JW, Cummings RM, Bowes LJ, Ridley RM, Green AR: Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 2003;34:2228–2233.
53.
Lees KR, Sharma AK, Barer D, Ford GA, Kostulas V, Cheng YF, Odergren T: Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke 2001;32:675–680.
54.
Jonsson S, Cheng YF, Edenius C, Lees KR, Odergren T, Karlsson MO: Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke. Clin Pharmacokinet 2005;44:863–878.
55.
Fisher M, Lees K, Papadakis M, Buchan AM: NXY-059: brain or vessel protection. Stroke 2006;37:2189–2190.
56.
Weimar C, Kurth T, Kraywinkel K, Wagner M, Busse O, Haberl RL, Diener HC: Assessment of functioning and disability after ischemic stroke. Stroke 2002;33:2053–2059.
57.
Saver JL: Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004;61:1066–1070.
58.
Saver JL, Kidwell C, Eckstein M, Ovbiagele B, Starkman S: Physician-investigator phone elicitation of consent in the field: a novel method to obtain explicit informed consent for prehospital clinical research. Prehosp Emerg Care 2006;10:182–185.
59.
Fogelholm R, Palomaki H, Erila T, Rissanen A, Kaste M: Blood pressure, nimodipine, and outcome of ischemic stroke. Acta Neurol Scand 2004;109:200–204.
60.
Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, Norris J: Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 2000;31:347–354.
61.
Ikonomidou C, Turski L: Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 2002;1:383–386.
62.
Albers GW, Goldstein LB, Hall D, Lesko LM: Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. JAMA 2001;286:2673–2682.
63.
Gandolfo C, Sandercock P, Conti M: Lubeluzole for acute ischaemic stroke. Cochrane Database Syst Rev 2002;1:CD001924.
64.
Furuya K, Takeda H, Azhar S, McCarron RM, Chen Y, Ruetzler CA, Wolcott KM, DeGraba TJ, Rothlein R, Hugli TE, del Zoppo GJ, Hallenbeck JM: Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study. Stroke 2001;32:2665–2674.
65.
Brott T, Bogousslavsky J: Treatment of acute ischemic stroke. N Engl J Med 2000;343:710–722.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.